Case study: preclinical PK drug screen using the Gyrolab immunoassay platform

Written by Frontage Laboratories
Automation Biopharmaceuticals
Biotechnology investments focus on companies developing medical and technological advancements. These stocks can offer high growth potential but come with significant risk

Summary

This case study highlights the benefits of using the automated Gyrolab platform for immunoassay studies limited by sample volume. The Gyrolab platform performed the immunoassays using nanoliter-scale volumes, which is unachievable in ELISA or MSD.

Challenge

Preclinical animal studies are a critical step in the drug development process. Due to the size of experimental animals, especially rodents, the volume of collected samples are usually small. A sponsor came to Frontage requesting a non-GLP PK drug screen on rodents; the volume of the collected sample was ~50µl, which is insufficient for a traditional ELISA or MSD assays.

Image Source: https://www.gyrosproteintechnologies.com/gyrolab-cds-learn-more

Solution

Frontage’s team, working with this sponsor, recommended the use of Gyrolab Technology. This platform can run automated immunoassays at nanoliter-scale levels and was determined to be best suited platform for this sponsor’s request. With the recommendation of our experienced scientific team and the clear advantages of using the Gyrolab immunoassay platform, we developed a method with 10-fold MRD using only 5µl of sample for analysis.

Result

Currently more than 30 drug screening studies have been completed. The volume of collected sample was sufficient for sample analysis and multiple times of repeat assays, where applicable.

In association with: